APRE
Aprea Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.41
P/S
15.89
EV/EBITDA
0.77
DCF Value
$2.25
FCF Yield
-288.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.4%
Operating Margin
-4631.1%
Net Margin
-4409.2%
ROE
-93.7%
ROA
-79.1%
ROIC
-100.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.3K | $-2.5M | $-0.32 |
| FY 2025 | $285.8K | $-12.6M | $-1.93 |
| Q3 2025 | $1.8K | $-3.0M | $-0.47 |
| Q2 2025 | $118.1K | $-3.2M | $-0.53 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.57
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.